---
format:
  revealjs:
    spotlight: true
    touch: true
    controls: true
    pointer: true
    center-title-slide: false
    transition: fade
    transition-speed: fast
    scrollable: true
    slide-number: true
    incremental: false
    multiplex: true
    chalkboard: true
    theme: [custom.scss]
    filters:
     - highlight-text
bibliography: references.bib
lightbox: true
csl: diagnostic-microbiology-and-infectious-disease.csl
revealjs-plugins:
  - pointer
---

## Posaconazole therapeutic drug monitoring: <br>Where do we stand? {background-image="images/bloodsample.jpg" background-opacity="0.2"}

<br> <br> <br> <br>

**Russell E. Lewis**, **Pharm.D., FCCP** <br> Associate Professor of Infectious Diseases <br> Department of Molecular Medicine <br> University of Padua <br> <br>

![](images/University_of_Padua_seal.svg){width="125"}

## Disclosures {background-image="images/bloodsample.jpg" background-opacity="0.2"}

<br>

-   **Royalities:** UptoDate

-   **Research support:** Gilead Inc.

-   **Speaking:** Avir, Gilead, F2G, Pfizer

-   **Advisory:** Gilead, F2G, Synexis, Basilea, Cidara

::: aside
Last 5 years
:::

## Timeline of posaconazole TDM {.smaller}

```{mermaid}
%%{init: {
    'theme': 'base',
    'themeVariables': {
      'fontFamily': "Arial, sans-serif",
      'fontSize': '28px',
      'primaryColor': '#cfe2f3',
      'primaryTextColor': '#000000',
      'primaryBorderColor': '##ffffff',
      'lineColor': '#000000',
      'secondaryColor': '#d9ead3',
      'tertiaryColor': '#fce5cd'
    }
  }
}%%


timeline
section Suspension era- <br>TDM essential for all patients
  2006: Suspension formulation approved by the FDA, EMA
  2007: Prophylaxis and refractory IA data: Cornely et al. NEJM: Ullmann et al. NEJM: Walsh et al. CID 
  2010: TDM targets- Prophylaxis > 700 ng/mL treatment: Jang et al. CP&T 
  2012: "Real-life" validation of TDM targets: Dolton et al. AAC: Many other single-centre studies
section New formulations- <br> TDM still essential?
  2013: FDA approval of posaconazole ER tablets 
  2015: FDA approval of posaconazole IV formulation: Cornely et al. JAC
  2021: Phase III treatment data: Maertens et al. Lancet 
  2023: No observed ER relationship: Maertens et al. Clin Drug Investig
section Targeted TDM- <br> which patients?
  2025: Extreme variablity in ICU : Single centre studies : Roberts et al. <br> SAFE-ICU <br> Inten Care Med
  
```

::: aside
[@cornely2007; @ullmann2007; @walsh2007; @jang2010; @cornely2017; @maertens2021; @maertens2023; @roberts2025]
:::

## Case #1: Posaconazole prophylaxis post HSCT

<br>

-   **56 year-old female patient with AML undergoing haploidentical HSCT with BuFLU conditioning + TBI**

-   **Prophylaxis:**

    -   Micafungin 50 mg/day starting at neutropenia onset until completion of post-stem cell infusion of cyclophosphamide on Day+5

    -   Posaconazole ER tablets 300 mg BID day #1, then 300 mg daily

    -   Patient is also receiving letermovir, tacrolimus, TMP/SMX and valacyclovir

    -   On day +9 of transplant when patient has ANC 0.1 and Grade 2 mucositis, a posaconazole trough concetration is ordered

    -   Result= 450 ng/mL (Target \> 700 ng/mL)

## Mucositis grading system

![](images/Screenshot%202025-02-13%20at%2021.33.47.png){fig-align="center" width="1000"}

<div>

[@sonis1999]

</div>

## Reduced bioavailibility in the setting of <br> intestinal mucositis

![](images/Screenshot%202025-02-13%20at%2021.24.50.png){fig-align="center" width="800"}

::: aside
[@jansen2022] <br> Mucositis onset assessed through citrulline serum concentrations
:::

## Dose-escalation during mucositis? {background-image="images/arrow.png" background-opacity="0.2"}

<br>

-   Use IV formulation (if available)

-   Pragmatic increase of loading dose to 400 mg BID on day 1, then 400 mg daily

    -   Higher doses are generally well-tolerated during treatment of triazole-resistant isolates

        -   Hepatotoxicity, pseudohyperaldosteronism (Serum levels \> 3000 ng/mL)

        -   Not always easy to predict who develops severe mucositis-citrulline test not used clinically

        -   Follow oral food intake?

-   **Will higher doses reduce the risk of breakthrough fungal disease?**

::: aside
[@schauwvlieghe2020]; [@nguyen.etal_2020b]; [@davis.etal_2020b]; [@pham.etal_2016a]
:::

## Delayed attainment of target posaconazole <br>trough concentrations after HSCT

![](images/Screenshot%202025-02-13%20at%2022.02.55.png) <br> <br> <br>

::: aside
[@cao2024]
:::

## Delayed attainment of target posaconazole <br>trough concentrations after HSCT

![](images/posaconazole.png){fig-align="center"}

[@cao2024]

## Delayed attainment of target posaconazole <br>trough concentrations after HSCT

![](images/pos.png){fig-align="center" width="800"}

<div>

[@cao2024]

</div>

## Case #2: Posaconazole precision dosing?

<br> <br>

::::: columns
::: {.column width="50%"}
![](images/Screenshot%202025-02-14%20at%2006.45.38.png){fig-align="center" width="414"}
:::

::: {.column width="50%"}
-   65 year-old patient with AML, fever, severe respiratory difficulty following consolidation chemotherapy -absolute neutrophil count 250
-   Patient was receiving voriconazole, but switched to isavuconazole following development of mental status changes
-   Influenzae A positive
-   Bronchoscopy positive for *Aspergillus terreus*, galactomannan 3.1
-   Patient has new onset of altered mental status and confusion
:::
:::::

## *Aspergillus terreus* antibiogram

<br>

| Antifungal     | MIC (mg/L) | EUCAST interpretation |
|----------------|------------|-----------------------|
| Amphotericin B | 4          | IE                    |
| Anidulafungin  | \>4        | IE                    |
| Caspofungin    | \>4        | IE                    |
| Micafungin     | \>4        | IE                    |
| Isavuconazle   | 2          | R                     |
| Voriconazole   | 1          | IE, ECOFF=2           |
| Posaconazole   | 0.06       | S, breakpoint= 0.25   |

::: aside
IE- insufficient evidence for breakpoint, ECOFF- Epidemiological cut-off, S- susceptible, <br>R- resistant
:::

## Clinical management

<br> <br>

-   Patient is switched to posaconazole ER tablets 300 mg BID day 1, then 300 mg daily
-   After 5 days a posaconazole trough is sent, result =710 ng/mL
-   Patient is clinical stable, improving respiratory status and afebrile

## Do we need to increase the dose?

![](images/Screenshot%202025-02-14%20at%2010.53.51.png){fig-align="center" width="600"}

::: aside
Posaconazole Css 1 mg/L covers A. fumigatus up to breakpoint of 0.25 mg/L

[@Lewis2014]
:::

## Or just assume the MIC is 0.25 mg/L?

![](images/Screenshot%202025-02-14%20at%2011.09.07.png){fig-align="center"}

<div>

[@mouton.etal_2018a]

</div>

## One other twist....

<br>

::::: columns
::: {.column width="50%"}
![](images/Screenshot%202025-02-14%20at%2006.45.38.png){fig-align="center" width="414"}
:::

::: {.column width="50%"}
-   Patient has a serum albumin of 2.2 mg/dL
-   Trough treatment target 1000-3750 ng/L: free drug (99%) 10-37.5 ng/mL
-   Total posaconazole concentrations is decreased, but unbound concentration is the same and percent unbound increases \~ 2fold
-   Because TDM results are not reported as free drug, should we "correct" free-drug posaconazole concentrations?
:::
:::::

## Corrected total concentration of posaconazole?

<br>

$$
C_{corr}= C_{obs}\frac{1}{\left( 0.01 + 0.99\frac{Alb}{4.4} \right)}
$$

<center>*simplified equation*</center>

$$
C_{corr}= C_{obs}\frac{4.4}{Alb}
$$

<center>*corrected conentration*</center>

$$
C_{corr}= 1400 ng/mL
$$

::: aside
*Alb*- serum albumin

[@nix.etal_2024]
:::

## Are the assumptions valid or close enough?

![Percent unbound posaconazole versus unbound concentrations](images/Screenshot 2025-02-14 at 12.00.10.png){fig-align="center"}

<div>

[@jansen.etal_2022]

</div>

Balancing increased precision and sophistication vs. practicality?

![](images/Screenshot 2025-02-14 at 12.03.41.png){fig-align="center"}

::: aside
[@jansen.etal_2024]
:::

## The reality to bring this forward?

![](images/disparity.png){fig-align="center"}

<div>

[@Salmanton-Garc√≠a2023]

</div>

## References
